7Baggers
 verve therapeutics acquisition marks new chapter in gene editing  AD HOC NEWS Sat, 15 Nov 2025 14:31:04 GMT
 a gene-editing therapy cut cholesterol levels by half  WIRED Sat, 08 Nov 2025 14:56:00 GMT
 bitterroot bio raises $145m series a to transform cardiovascular therapeutics  Longevity.Technology Fri, 07 Nov 2025 16:49:05 GMT
 published on: 2025-10-31 05:49:39  newser.com Fri, 31 Oct 2025 10:49:39 GMT
 fda places formal hold on two intellia crispr trials  BioPharma Dive Thu, 30 Oct 2025 07:00:00 GMT
 published on: 2025-10-30 01:19:27  newser.com Thu, 30 Oct 2025 06:19:27 GMT
 published on: 2025-10-28 01:55:22  newser.com Tue, 28 Oct 2025 06:55:22 GMT
 published on: 2025-10-27 19:55:27  newser.com Tue, 28 Oct 2025 00:55:27 GMT
 published on: 2025-10-26 19:10:13  newser.com Mon, 27 Oct 2025 00:10:13 GMT
 published on: 2025-10-26 04:07:23  newser.com Sun, 26 Oct 2025 09:07:23 GMT
 published on: 2025-10-24 04:58:14  newser.com Fri, 24 Oct 2025 09:58:14 GMT
 a new era for cell and gene therapy signals new market opportunities  MedCity News Fri, 24 Oct 2025 07:00:00 GMT

Verve Therapeutics
(NASDAQ:VERV) 

VERV stock logo

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.

Founded: 2018
CEO / Founder: Sekar Kathiresan 
Sector:
Industry:

Share this website to your friends